BTAI (BioXcel Therapeutics) Forward Dividend Yield % : 0.00% (As of Mar. 23, 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Forward Dividend Yield %?

As of today (2025-03-23), the Forward Annual Dividend Yield of BioXcel Therapeutics is 0.00%.

As of today (2025-03-23), the Trailing Annual Dividend Yield of BioXcel Therapeutics is 0.00%.

BTAI's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.44
* Ranked among companies with meaningful Forward Dividend Yield % only.

BioXcel Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of BioXcel Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, BioXcel Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Forward Dividend Yield % falls into.

BioXcel Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

BioXcel Therapeutics (NAS:BTAI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

BioXcel Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

BX20:Germany

Address

555 Long Wharf Drive, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Executives

Richard I Steinhart	officer: Chief Financial Officer	125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez	officer: SEE REMARKS	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Frank Yocca	officer: Chief Scientific Officer	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vimal Mehta	director, officer: CEO, President, Secretary	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vincent O'neill	officer: Chief Medical Officer	2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Matthew T. Wiley	officer: CHIEF COMMERCIAL OFFICER	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Krishnan Nandabalan	director, 10 percent owner	228 VILLAGE POND ROAD, GUILFORD CT 06437
Alka Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello	10 percent owner	10 TEMPLETON ROAD, WALLINGFORD CT 06492
Pardeep Kumar Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437